Anne-Marie Duliege, MD
Almost half of adult patients with previously treated chronic immune thrombocytopenia (ITP) achieved major responses with the SYK inhibitor fostamatinib (Tavalisse), according to an analysis of pooled clinical study data.
The incidence of serious adverse events (SAEs) was 27% (n = 39). The incidence of SAEs probably/possibly related to fostamatinib was 6%, consisting of diarrhea and neutropenia in 2 patients each and increased transaminase, atrial fibrillation, upper respiratory tract infection, sepsis, pneumonia, pyrexia, and hypertensive crisis in 1 patient each.
Duliege AM, Arnold D, Boccia R, et al. Two-year safety and efficacy outcomes with fostamatinib in adult patients with immune thrombocytopenia (ITP): open-label extension to the phase 3 trial program. Presented at: ASH Annual Meeting and Exposition; December 4-8, 2018; San Diego, CA. Abstract 736.
... to read the full story